This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

What it means for patients - The compounded versions of the drug were originally sold to combat a brand-name shortage ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Injectable medications originally developed for the treatment of diabetes are also effective for weight loss and have surged ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Phase 1 MAD Data for DA-1726 On April 15, 2025, MetaVia Inc. (NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ...

This includes the likes of Ozempic, Mounjaro, Saxenda and Wegovy, which can sell for up to £269 a month. The drugs have proved popular with overweight Brits who want to rapidly lose weight and ...

Are there signs the storm created by Donald Trump's tariffs could be calming? Global markets have rebounded following the US president's announcement of a 90-day pause on most tariffs, prompting ...

John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of Medicare ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type ... it’s really important to work with a doctor on dosing of both the GLP-1 and insulin. Shah says he would caution people ...